Journal of Cutaneous Medicine and Surgery · 2001 · 19 citations · 8 references
MedicineDermatologyPharmacotherapyDermatopathologyHistopathologyHypersensitivityAutoimmune Blistering DiseasesAutoimmune Skin DiseasesDrug-induced Skin ReactionsEpidermolysis BullosaImmunopathology Of SkinInflammatory DermatosesBullous DermatosesCutaneous BlisteringDapsone TherapyImmunofluorescence FindingsImmunofluorescence StainingIndirect Immunofluorescence AssayPrednisone UseSubepidermal Blistering Disorders
Background: Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is frequently resistant to therapy. Objective: A 58-year-old man who had a one-year history of a bullous eruption involving the hands, forearms, trunk, scalp, and oral mucosa. Histopathology revealed a subepidermal bulla, and direct and indirect immunofluorescence studies were consistent with EBA. The patient failed respond to niacinamide and tetracycline and oral prednisone 40 mg per day. Methods: Complete control of his blistering was achieved within two months of initiating oral dapsone, 150 mg per day. Conclusion: Dapsone may be an effective agent for some patients with EBA.
8
Bullous Eruption of Systemic Lupus Erythematosus
Russell P. Hall · Annals of Internal Medicine · 1982 · 225 citations
Medicine, Dermatology, Pathology +10
Clearing of epidermolysis bullosa acquisita with cyclosporine
Laura Crow, Jeremy P. Finkle, W. Ray Gammon et al. · Journal of the American Academy of Dermatology · 1988 · 103 citations
Medicine, Dermatology, Pathology +8
Epidermolysis Bullosa Acquisita in Childhood
Claire Callot-Mellot · Archives of Dermatology · 1997 · 84 citations
Medicine, Dermatology, Pediatrics +16